Biotechnology

Complete Genomics to Announce New Product Launches at AGBT General Meeting

SAN JOSE, Calif., Jan. 24, 2023 /PRNewswire/ -- Complete Genomics Inc. , a global life science tools leader and subsidiary of MGI Tech Co., Ltd. ("MGI"), today announced it plans to launch three new products at the Advances in Genome Biology and Techn...

2023-01-24 20:30 2324

CARsgen Presents Results on Anti-Claudin18.2-mAb AB011 at ASCO GI

SHANGHAI, Jan. 20, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces thata poster presentation highlighting the Phase 1 preliminary result...

2023-01-20 21:50 4617

SK bioscience Appoints New Executives to Accelerate New Growth Strategies

* Two biopharmaceutical experts join SK bioscience to strengthen the future strategies * With recruitment of global talent and capabilities accumulated during the COVID-19 pandemic, SK bioscience will continue to achieve sustainable growth SEOUL, South Korea, Jan. 20, 2023 /PRNewswire/ -- SK ...

2023-01-20 20:00 2850

DualityBio Announces DB-1303 Granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the Treatment of Advanced, Recurrent or Metastatic Endometrial Carcinoma with HER2 Overexpression

PRINCETON, N.J., SHANGHAI and SUZHOU, China, Jan. 20, 2023 /PRNewswire/ -- Duality Biologics ("DualityBio"), a clinical-stage biotech company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers and autoimmune diseases, announced that the U.S. Food...

2023-01-20 18:00 3349

BriSTAR Immunotech To Present its Novel Cell Therapy for Acute Myeloid Leukemia at the AACR Special Conference on AML and MDS

TORONTO, Canada and BEIJING, Jan. 20, 2023 /PRNewswire/ -- BriSTAR Immunotech, a clinical-stage cell therapy company, announced today it will showcase its T-cell receptors (TCR) and antigen receptor (STAR)-T cell therapy technology platform at theAmerican Association for Cancer Research (AACR) <...

2023-01-20 13:10 2263

$412.5 million! Mabwell Announces Exclusive Licensing Agreement with DISC MEDICINE, INC. for Innovative Drug Candidates of Hematologic Diseases

SAN DIEGO, Jan. 19, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, announced its wholly-owned subsidiary Mabwell Therapeutics has entered into an agreement with DISC MEDICINE, INC. ("Disc") about 9MW3011 (R&D code in t...

2023-01-20 09:50 2359

NEW THERAPY TO TREAT RARE GASTROINTESTINAL STROMAL TUMOUR APPROVED FOR NEW ZEALAND PATIENTS

* QINLOCK® (ripretinib) now Medsafe approved for GIST patients in NZ * QINLOCK now being considered by PHARMAC for reimbursement * Data from the INVICTUS Phase 3 study shows QINLOCK reduces risk of disease progression or death by 85%1, 2 SINGAPORE and AUCKLAND, New Zealand, Jan. 19, 2023 /PR...

2023-01-20 02:00 2471

Seragon Announces RESTORIN®, the Most Advanced Anti-Aging Nutraceutical to Date

IRVINE, Calif., Jan. 19, 2023 /PRNewswire/ -- Seragon Biosciences, Inc. today announced the launch of RESTORIN®, an advanced nutraceutical for healthy aging. RESTORIN integrates a series of patented technologies fromHarvard University, Mayo Clinic, and Scripps Research to boost cellular nicotinam...

2023-01-19 23:10 4165

Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma's Global Infrastructure to Provide Broad Access to Deuruxolitinib for Patients with Alopecia Areata Strengthens Sun Pharma's Global De...

2023-01-19 23:05 4364

Hepagene Therapeutics Reports Positive Top-line Results for Phase 2a RISE Study of FXR Agonist HPG1860 in Patients with NASH

SHANGHAI, Jan. 19, 2023 /PRNewswire/ -- Hepagene Therapeutics, Inc. a clinical stage biopharmaceutical company focusing on developing novel therapies for patients with chronic liver diseases, today reported positive top-line results from the Phase 2a RISE clinical trial of HPG1860, a next gene...

2023-01-19 23:00 2466

Prenetics Announces Dr. Bayju Thakar as Chief Executive Officer of Prenetics EMEA

LONDON and HONG KONG, Jan. 19, 2023 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE) a leader in genomic and diagnostic testing, today announced an executive leadership change to ensure the company realizes the full potential of its broad genetics and digital testing platform and as a commi...

2023-01-19 18:56 2983

Tigermed Completes Acquisition of Marti Farm

HANGZHOU, China and ZAGREB, Croatia, Jan. 19, 2023 /PRNewswire/ -- Tigermed (300347.SZ/3347.HK), a leading global provider of clinical research solutions across the full lifecycle of global biopharmaceutical and medical device products, announced today the completion of its acquisition of Marti F...

2023-01-19 14:59 4318

China's First and Only Approved Third-Generation BCR-ABL Inhibitor Olverembatinib Included into the 2022 National Reimbursement Drug List

SUZHOU, China, and ROCKVILLE, MD, Jan. 18, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, and Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), today an...

2023-01-19 11:45 2310

Innovent Announces Inclusion in the China National Reimbursement Drug List (NRDL) of TYVYT in Two New Indications, Olverembatinib for the First Listing, BYVASDA, HALPRYZA and SULINNO in Multiple New Indications

ROCKVILLE, Md. and SUZHOU, China, Jan. 18, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology an...

2023-01-18 21:34 3212

Novavax Nuvaxovid COVID-19 Vaccine Approved in South Korea as an Adult Booster

GAITHERSBURG, Md., Jan. 18, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that partner SK bioscience has received expanded manufacturing and marketing...

2023-01-18 21:00 2682

Cambrex Completes Acquisition of Snapdragon Chemistry, a Leader in Continuous Flow API Development Services

EAST RUTHERFORD, N.J., Jan. 18, 2023 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced that it has completed its acquisition of Snap...

2023-01-18 19:00 2791

Natus Medical Incorporated Announces Closing of Acquisition of Micromed Holding SAS

Newly merged organization brings together innovative neurodiagnostic and neuromonitoring solutions and experienced teams to offer a broader portfolio of products, services and support to customers worldwide. MIDDLETON, Wis., Jan. 18, 2023 /PRNewswire/ -- Natus Medical Incorporated (the "Company"...

2023-01-18 18:03 2999

WFH Gene Therapy Registry: now live!

MONTREAL, Jan. 18, 2023 /PRNewswire/ -- To ensure patient safety remains at the forefront of the work of the World Federation of Hemophilia (WFH), we have developed a registry to monitor the long-term safety and efficacy of gene therapy for people with hemophilia: the WFH Gene Therapy Registry (G...

2023-01-18 18:00 2253

UNIONCOMMUNITY announces its participation at Intersec 2023, Dubai

SEOUL, South Korea, Jan. 18, 2023 /PRNewswire/ -- UNIONCOMMUNITY, a global leading contactless multimodal biometric company, announced its participation at Intersec 2023. The universal exhibition, Intersec 2023, from 17-19 January, covered the wide range of topics in the security industry, includ...

2023-01-18 17:28 1819

Keymed Biosciences | The Latest Results from the Phase Ia Clinical Study of CMG901 was presented at the 2023 ASCO GI CANCERS SYMPOSIUM

CHENGDU, China, Jan. 17, 2023 /PRNewswire/ -- Keymed Biosciences Inc. (Stock Code: 02162 HK) is pleased to announce that the latest data from the Phase Ia dose-escalation trial of CMG901 (Claudin 18.2 antibody drug conjugate), a novel drug candidate, for advanced solid tumors will be presented as...

2023-01-18 09:52 1948
1 ... 128129130131132133134 ... 307